Navigation Links
BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.

QUINCY, Mass., July 18 /PRNewswire/ -- BioEnergy International, LLC (BioEnergy), a privately-held, biotech-based developer and manufacturer of next-generation, renewable biochemicals and biofuels, announces the acquisition of certain assets of OmniGene Bioproducts, Inc. (OBI) and the integration of its current employees. OBI, currently based in Cambridge, MA, possesses core competencies and proprietary Bacillus host technology and metabolic pathway engineering expertise to develop efficient strains for the fermentative production of commercial products.

(Logo: )

OBI's scientists are industry leaders with a broad range of expertise in molecular biology, cell biology, and fermentation technology, with Bacillus subtilis, Corynebacterium glutamicum, Escherichia coli, Streptomyces, and yeast species. "The addition of Jan Pero, Rog Yocum, and their world-renowned R&D team, as well as their library of proprietary strains, organisms and plasmids, represents an enormous complement to and expansion of BioEnergy's existing cutting-edge microbial platform development, said Stephen J. Gatto, Chairman and Chief Executive Officer of BioEnergy. "OBI's track record of successfully commercializing products over the years has clearly set them apart in the marketplace. We look forward to their immediate contributions toward making BioEnergy the premier industrial bioproducts player in the industry."

The OBI personnel will be incorporated into BioEnergy's existing Research & Development Group, located in Woburn, MA. "As attractive as OBI's proprietary organism portfolio is, the real strength of this transaction is the addition of this entire team's core competency and track record of metabolic pathway engineering," said Dr. Joseph Glas, Senior Vice President of BioEnergy's R&D Group. "The OBI scientists represent an immediate enhancement and growth of BioEnergy's strain improvement & development program for biochemicals and biofuels."

Dr. Janice Pero, President of OBI, has over 25 years of experience in research management and is an expert in gene regulation, excelling in the genetic engineering and molecular biology of Bacillus and Streptomyces species. Dr. Pero was an Associate Professor at Harvard University, and a founder of BioTechnica International in 1981, before starting OBI in 1995. Dr. Pero received a Ph.D. in Biochemistry and Molecular Biology from Harvard University.

Dr. Rog Yocum, Senior Program Director at OBI, is an expert in genetic engineering of biochemical pathways in bacteria and yeast, and genetic engineering of industrial yeasts. Dr. Yocum was a founder of BioTechnica International in 1981 and served as a Program Director before joining OBI as a founding member. Dr. Yocum received a Ph.D. in Biochemistry from Harvard University.

"We are pleased that OBI's approach, which combines our expertise in genetic engineering with computer-controlled fermentation technology to develop highly productive strains that convert inexpensive sugars into high value specialty products, is completely complementary to BioEnergy's strategic mission," said Dr. Pero. "We are excited to combine our resources in the development of further proprietary technology and strains."

About OBI

OmniGene Bioproducts, Inc. is a privately held biotech company that has been active in the field of metabolic engineering for more than 12 years, with a focus on producing vitamins and amino acids by fermentation from renewable resources. OBI's small but highly productive group of scientists has been responsible for the development of food grade bacteria that produce riboflavin (vitamin B2), pantothenic acid (vitamin B5), and the amino acid methionine. In all cases, the organisms and processes developed by OBI's scientists have set records for the highest published titers of their respective products. For more information visit

About BioEnergy

BioEnergy International, LLC is a privately held science and technology company focused on developing innovative biorefineries using novel biocatalysts for the production of high-value renewable fuels and bio-based polymer precursors and intermediates used by energy companies, specialty chemical companies, and manufacturers in a wide range of consumer products. Led by a world-renowned team of molecular biologists, engineers, and chemists, BioEnergy utilizes proprietary technology to advance the development of low- cost cellulosic sugars for the sustainable production of high-value specialty chemicals and renewable fuels. The company's strategic vision is to replace a barrel of crude with a pound of sugar derived from waste for the manufacture of everything from the fuel we put in our cars to the plastics and fabrics we use in our everyday lives. For more information, visit

Contact: Stephen J. Gatto, Chairman and Chief Executive Officer

Samuel G. McConnell, Sr. Vice President, Corporate Development

(617) 657-5200

SOURCE BioEnergy International, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock
2. Raj Khankari Named Bioenergy, Inc., CEO
3. Atlantica BioEnergy Task Force Unveiled
4. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
5. BioEnergy International Facility Opens in Bay State
6. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
7. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
8. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
9. Chindex International, Inc. Quantifies Fourth Quarter Charges
10. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
11. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
Post Your Comments:
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):